The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like What if neuroplasticity research targeted the HGF c Met pathway? Dihexa (PNB 0408) is an angiotensin IVderived peptide studied in preclinical models for its role in synaptogenesis and cognitive signaling mechanisms. Human data remains limited. What is dihexa, its mechanism of action via the HGF c Met pathway, and its safety and clinical use? 2023 FDA approvals: unprecedented volume at moderate value The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York